Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates SignPath Pharma has begun efforts to develop Lipocurc, an intravenous liposomal curcumin formulation, to treat acute respiratory distress syndrome (ARDS) caused by Covid-19.
Lipocurc suppresses the pro-inflammatory cytokines that cause severe lung damage associated with ARDS. Some Covid-19 patients develop fatal lung damage due to a cytokine storm, characterised by a significant increase in pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-alpha), interleukin-1 beta, interleukin-6 and interleukin-8.
According to the company, Lipocurc safely suppresses interleukin-6 by 83%, along with TNF-alpha by 77% and interleukin-1 beta by 85%.